|
ALOGENE THERAPEUTICS, Inc. (Allo) Avaliação DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Allogene Therapeutics, Inc. (ALLO) Bundle
Avalie as perspectivas financeiras da Alogene Therapeutics, Inc. (Allo) como um especialista! Esta calculadora (Allo) DCF fornece dados financeiros pré-preenchidos, juntamente com a flexibilidade para modificar o crescimento da receita, o WACC, as margens e outras suposições essenciais para se alinhar às suas projeções.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | 38.5 | .2 | .1 | .1 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | -99.37 | -60.91 | -40.07 | -40.07 | -40.07 | -40.07 | -40.07 |
| EBITDA | -179.9 | -250.8 | -169.7 | -321.2 | -300.3 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | -441 | -132197.94 | -316097.89 | -20 | -20 | -20 | -20 | -20 |
| Depreciation | 5.0 | 11.5 | 10.5 | 14.3 | 14.2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 27.16 | 5882.72 | 14946.32 | 85.43 | 85.43 | 85.43 | 85.43 | 85.43 |
| EBIT | -184.9 | -262.3 | -180.2 | -335.5 | -314.5 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | -468.16 | -138080.66 | -331044.21 | -20 | -20 | -20 | -20 | -20 |
| Total Cash | 588.9 | 1,032.1 | 809.5 | 576.5 | 448.7 | .1 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .2 | .5 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2.4 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 0 | 0 | 0 | 40 | 40 | 40 | 40 | 40 |
| Inventories | -60.7 | -207.0 | -20.0 | -62.5 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | -52.02 | -25700 | 0 | 9.6 | 9.6 | 9.6 | 9.6 | 9.6 |
| Accounts Payable | 9.3 | 10.4 | 10.3 | 13.9 | 5.9 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 26.64 | 5716.05 | 6207.37 | 85.33 | 85.33 | 85.33 | 85.33 | 85.33 |
| Capital Expenditure | -50.8 | -66.0 | -21.4 | -5.2 | -1.5 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | -55.72 | -2136.21 | -1595.79 | -51.14 | -51.14 | -51.14 | -51.14 | -51.14 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -184.6 | -244.8 | -171.7 | -332.7 | -314.5 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -162.8 | -149.4 | -369.8 | -277.5 | -372.3 | -5.9 | .0 | .0 | .0 | .0 |
| WACC, % | 7.01 | 6.95 | 6.97 | 7 | 7.01 | 6.99 | 6.99 | 6.99 | 6.99 | 6.99 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -5.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -6 | |||||||||
| Net Debt | 12 | |||||||||
| Equity Value | -17 | |||||||||
| Diluted Shares Outstanding, MM | 157 | |||||||||
| Equity Value Per Share | -0.11 |
What You Will Get
- Genuine Allogene Data: Preloaded financials – encompassing revenue to EBIT – derived from actual and projected figures.
- Comprehensive Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- Immediate Valuation Updates: Automatic recalculations to assess the effects of changes on Allogene Therapeutics' fair value.
- Flexible Excel Template: Designed for quick modifications, scenario analysis, and detailed forecasts.
- Efficient and Precise: Avoid the hassle of building models from the ground up while ensuring accuracy and adaptability.
Key Features
- Comprehensive Data: Allogene Therapeutics’ historical financial records and pre-filled projections.
- Customizable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Calculations: View Allogene Therapeutics’ intrinsic value update instantly.
- Visual Analytics: Dashboard graphs illustrate valuation outcomes and essential metrics.
- Designed for Precision: A reliable tool for analysts, investors, and finance professionals.
How It Works
- Download the Template: Gain immediate access to the Excel-based ALLO DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically recalculates Allogene Therapeutics’ intrinsic value.
- Test Scenarios: Experiment with different assumptions to assess potential valuation variations.
- Analyze and Decide: Leverage the results to inform your investment or financial analysis.
Why Choose This Calculator for Allogene Therapeutics, Inc. (ALLO)?
- Accurate Data: Up-to-date Allogene financials provide trustworthy valuation outcomes.
- Customizable: Tailor essential metrics like growth rates, WACC, and tax rates to fit your forecasts.
- Time-Saving: Ready-to-use calculations save you from starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Easy-to-navigate design and clear instructions ensure accessibility for all users.
Who Should Use Allogene Therapeutics, Inc. (ALLO)?
- Healthcare Investors: Make informed decisions with a cutting-edge biotechnology investment tool.
- Biotech Analysts: Streamline your analysis with a customizable model tailored for gene therapy insights.
- Consultants: Effortlessly modify the template for client discussions or strategic reports.
- Life Sciences Enthusiasts: Enhance your knowledge of innovative therapies using real-world case studies.
- Educators and Students: Utilize it as a hands-on resource in courses focused on biotechnology and healthcare.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Allogene Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Allogene Therapeutics, Inc. (ALLO).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.